Medicare may have released a plan to restrict access to the controversial Biogen Alzheimer’s drug, but the biggest losers may actually be other drug makers readying treatments for the debilitating disease.
The question is whether they encounter such difficulties and, if so, to what extent?
Under a draft policy announced by Medicare on Tuesday, any company developing a monoclonal antibody — the same type of injectable medicine as the troubled Biogen drug — would have to satisfy the same stiff requirements in order to win Medicare reimbursement. Coverage would be limited to patients enrolled in Phase 3, randomized clinical trials that are approved by the agency.
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect